Premium
Intranasal Midazolam: Pharmacokinetics and Pharmacodynamics Assessed by Quantitative EEG in Healthy Volunteers
Author(s) -
Hardmeier M,
Zimmermann R,
Rüegg S,
Pflüger M,
Deuster S,
Suter K,
Donzelli M,
Drewe J,
Krähenbühl S,
Fuhr P,
Haschke M
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.316
Subject(s) - midazolam , pharmacokinetics , pharmacodynamics , pharmacology , benzodiazepine , nasal administration , anesthesia , medicine , clinical pharmacology , electroencephalography , chemistry , sedation , receptor , psychiatry
The pharmacokinetics and pharmacodynamics of a highly concentrated cyclodextrin‐based intranasal (i.n.) midazolam formulation containing the absorption‐enhancer chitosan were studied in 12 healthy volunteers and compared with intravenous (i.v.) midazolam. The pharmacodynamic (PD) effects were assessed using quantitative electroencephalography (EEG). Maximal plasma concentrations of 63 and 110 ng/ml were reached at 8.4 and 7.6 min after 3 and 6 mg i.n. midazolam, respectively. After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18–25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively. A sigmoid maximum‐effect ( E max ) model indicated disequilibrium between plasma and effect‐site concentrations, with equilibration half‐lives of 2.1–4.8 min. The observed pharmacokinetic–PD (PK–PD) properties suggest that i.n. midazolam deserves to be evaluated as an easy and noninvasive method of administering a first benzodiazepine dose, e.g., in out‐of‐hospital emergency settings with no immediate i.v. access. Clinical Pharmacology & Therapeutics (2012); 91 5, 856–862. doi: 10.1038/clpt.2011.316